查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球呼吸道感染诊断市场 - 2022-2029
市场调查报告书
商品编码
1143389

全球呼吸道感染诊断市场 - 2022-2029

Global Respiratory Infectious Disease Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计 2021 年呼吸道感染诊断的市场规模将达到 639 亿美元，在预测期间（2022-2029 年）以 1.8% 的复合年增长率增长。

呼吸道感染是由感染呼吸系统（包括肺、咽喉和呼吸道）的病毒、细菌和其他微生物引起的。感染通常通过通常在打喷嚏、咳嗽和大笑时排出的粘液和唾液传播。还有许多空气中的飞沫和细菌可以在旅行中传播并导致呼吸道感染。此外，有些人因接触留在表面的微生物或接触受污染的手而被感染。

市场动态

市场受到呼吸系统疾病上升和产品技术进步的推动。

预计呼吸系统疾病负担加重和产品技术进步将推动市场增长。

慢性阻塞性肺病是一种进行性肺病，会导致气流减少。根据世界卫生组织 (WHO) 的数据，90% 的 COPD 死亡发生在低收入和中等收入国家。根据全球疾病负担研究，全球已报告约 2.51 亿例 COPD 病例。由于老龄化进程和人们生活方式的改变，预计未来会增加。因此，早期诊断和早期治疗极为重要，有望推动市场增长。

最近随着 COVID-19 感染在全球蔓延的大流行是预计在预测期内增加诊断需求的主要因素。根据目前的统计数据，2020 年 4 月全球有 608 万人感染了 COVID-19 疾病，这可能会影响对快速诊断检测的需求。预计这一因素将在预测期内推动呼吸道感染诊断市场的发展。

2020 年 1 月发布的数据显示，全球有 2,519 例实验室适合的中东呼吸综合征 (MERS) 病例，其中包括 866 例相关死亡病例。大部分报告病例发生在沙特阿拉伯（2121 例），包括 788 例相关死亡，病死率高达 37.1%。此外，COVID-19 大流行需要更快速的诊断。据统计，2020年5月，全球报告了近608万例COVID-19病例，增加了对该病早期诊断的需求。这一因素将在预测期内推动市场增长。

据推测，慢性阻塞性肺病（如慢性支气管炎、肺气肿和哮喘）以及肺病（如肺结核和肺炎）的负担激增，将推动呼吸道感染诊断市场的增长。此外，下呼吸道感染的增加将增加对早期检测的需求，进一步推动对诊断测试的需求。预计这些因素将在预测期内推动市场增长。

严格的监管框架和不利的报销政策是阻碍市场增长的主要因素。

但是，严格的监管框架、不利的报销政策以及患者意识低下将阻碍预测期内的市场增长。

COVID-19 影响分析

根据紧急使用授权，截至 2022 年 8 月，美国 FDA 已批准 439 项测试。 （欧盟）。用于检测 SARS-CoV-2 的新分子诊断测试充斥着市场。预计市场将受到快速的技术进步、便携性和成本效益的推动，以获得准确的结果。佳能医疗系统的 CT 系统“Aquilion Prime SP”于 2020 年 4 月推出，用于快速识别病毒感染。该产品包括一个集成的去污工具，该工具使用自动 UV-C 技术对整个设备在用于其他患者后进行消毒。

行业分析

全球呼吸道感染诊断市场根据波特五力、监管分析、报销分析、供应链分析、定价分析和技术进步等各种行业因素对市场进行了深入分析。我来了。

全球呼吸道感染诊断市场 - 细分分析

预计冠状病毒部分将占全球血压监测设备市场的最大市场份额

冠状病毒传染病部门占最大的市场份额。据世界卫生组织称，截至 2020 年 3 月 27 日，SARS-CoV-2 已传播到 150 多个国家，确诊病例超过 46 万例，死亡病例超过 2 万例。根据 2020 年 3 月在世界经济论坛上发表的一篇文章，在美国住院的 500 人中，20% 的人年龄在 20-44 岁之间，18% 的人年龄在 45-54 岁之间。这一因素将在预测期内推动市场增长。

预计患有心血管疾病、慢性呼吸道疾病、高血压和糖尿病等既往疾病的人的死亡率将高于平均水平。此外，据中国疾控中心称，男性比女性更容易感染病毒并患重病。男性死亡率为 2.8%，女性死亡率为 1.7%。预计这些因素将在预测期内推动市场增长。

区域介绍

由于呼吸道疾病负担的增加和吸烟率的上升，预计呼吸道感染诊断市场将以最高的复合年增长率增长，其中北美占世界的大部分。

根据疾病控制和预防中心的数据，2018 年美国的哮喘患病率在男性中约为 6.2%，在女性中约为 9.1%。此外，据报导，美国约有 6.2% 的人患有慢性阻塞性肺病。预计这些因素将在预测期内推动市场增长。

采用快速诊断测试来快速诊断呼吸道感染也是预计扩大该地区呼吸道感染诊断市场的关键因素之一。据CDC统计，2020年5月，实时逆转录□（RT）-PCR诊断试剂盒可有效检测呼吸道标本中的SARS-CoV-2病毒。美国食品和药物管理局还于 2020 年 2 月为该测试提供了紧急使用授权 (EUA)。预计这些因素将在预测期内推动市场增长。

竞争格局

由于存在多个国际和本地市场，全球呼吸道感染诊断市场竞争激烈。产品多样化、创收和不断增长的机会使市场更具竞争力。 Abbott Laboratories、Thermo Fisher Scientific Inc.、Alere, Inc.、Koninklijke Philips N.V.、Cardinal Health、COSMED、Smiths Group plc、NIHON KOHDEN CORPORATION、Becton、Dickinson and Company、F. Hoffmann-La Roche AG. 已成为领先市场企业与主要参与者正在利用产品开发、新产品发布、市场扩张和产品多元化战略来保持其市场地位。例如，2020 年 8 月，国际临床诊断专家 Novacyt 宣布推出获得 CE 标誌的聚合□链反应 (PCR) 呼吸检测试剂盒 Winterplex。该测试面板设计用于任何开放式 PCR 平台，包括我们的快速便携式 q32 仪器。

本报告提供了近 45+ 个市场数据表、40+ 个图表和 180 页有关全球呼吸道感染诊断市场的信息。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 第 3 章：按疾病类型划分的市场细分
  • 按测试类型划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 呼吸系统疾病负担加重
      • 技术进步
    • 约束因素
      • 严格的监管框架
  • 影响分析
  • 商机

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 保险报销分析

第6章按疾病类型

  • 冠状病毒感染
  • 中东呼吸综合征 (MERS)
  • 支气管哮喘
  • 慢性阻塞性肺疾病
  • 肺结核
  • 肺癌
  • 其他

第 7 章按测试类型

    • 图像检查
    • 机械检查
      • 肺活量计
      • 峰值流量检查
      • 血气检测
      • 肺功能检查
      • 阻塞性睡眠呼吸暂停综合征诊断测试
    • 体外诊断测试
      • 即时检测
      • 分子生物学诊断测试
    • 其他测试

第 8 章最终用户

  • 医院
  • 诊断中心
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 11 章公司简介

  • 雅培实验室
    • 公司简介
    • 产品组合和描述
    • 主要发展状况
    • 财务摘要
  • Becton Dickinson & Company
  • Thermo Fisher Scientific Inc
  • Alere, Inc
  • Koninklijke Philips N.V
  • Cardinal Health
  • COSMED
  • Smiths Group plc
  • NIHON KOHDEN CORPORATION
  • F. Hoffmann-La Roche AG.

第12章 全球呼吸道感染诊断市场-DataM

简介目录
Product Code: DMMD2675

Market Overview

Respiratory Infectious Disease Diagnostics Market size was valued US$ 63.9 billion in 2021 and is estimated to reach US$ YY billion by 2029, growing at a CAGR of 1.8% during the forecast period (2022-2029).

Respiratory infections are caused by virus, bacteria, and other microbes, which further infect the respiratory system including the lungs, throat, and airways. Spread of infections is often through mucus and saliva that is usually expelled when the person sneezes, coughs, or laughs. Few of the germs are also spread though droplets that spread through air and also spread through travelling, which causes respiratory infections. Furthermore, some people can be infected by touching the remaining microbes on the surface, or touching contaminated hands.

Market Dynamics

The market is driven is the rising burden of respiratory diseases and technological advancements in the products.

Rising burden of respiratory diseases and technological advancements in the products are expected to drive market growth

Chronic obstructive pulmonary disease is a progressive lung disorder which causes reduction in airflow. According to the World Health Organization, 90% of the COPD deaths occur in low- and middle-income countries. Approximately 251 million cases of COPD were reported globally as per the study of the Global Burden of Disease Study. It is expected to increase in the coming years due to increasing aging population and changing lifestyle of people. Therefore, early diagnosis and treatment is very important which is expected to boost the market growth.

Recent pandemic resulting into widespread COVID-19 infections across the globe is a major factor that is estimated to boost the demand for diagnosis during forecast period. As per current statistics, in April 2020, 6.08 million people across globe were infected with COVID-19 diseases, and this is likely to impact the need for rapid diagnostics testing. This factor is likely to boost the respiratory infectious diagnostics market during forecast period.

According to data published in January 2020, 2519 laboratory-conformed cases of Middle East respiratory syndrome (MERS), were reported, which includes 866 associated deaths globally. Majority of cases reported were from Saudi Arabia (2121 cases), including 788 related deaths with a higher fatality rate of 37.1%. Moreover, the emergence of COVID-19 pandemic has driven the demand for faster diagnosis. According to statistics, in May 2020, there were around 6.08 million COVID-19 cases reported globally, which boosts the need for early diagnosis of diseases. This factor will drive the growth of market in the forecast period.

Rapid rise in burden of chronic obstructive pulmonary disorders such as chronic bronchitis, emphysema, asthma, and other lung diseases such as tuberculosis, pneumonia, is estimated to boost the respiratory infectious disease diagnostics market. Furthermore, rising lower respiratory infectious disease drives the need for early detection, which further drivers the demand for diagnostics tests. This factor will drive the growth of market in the forecast period.

Stringent regulatory framework coupled with unfavorable reimbursement policies are one of the major factors hindering the growth of the market

However, a stringent regulatory framework coupled with unfavorable reimbursement policies and a low awareness rate among the patient population will hamper the growth of the market in the forecast period.

COVID-19 Impact Analysis

In accordance with Emergency Use of Authorization, the U.S. FDA had approved 439 tests as of August 2022. (EUAs). New molecular diagnostic tests for SARS-CoV-2 detection have flooded the market. The market is predicted to be driven by rapid technical improvements that produce accurate findings, portability, and cost-effectiveness. The Aquilion Prime SP CT system from Canon Medical Systems was introduced in April 2020 to identify viral infectious illnesses quickly. This product includes an integrated decontamination tool that sanitises the entire apparatus using automated UV-C technology after being used by additional patients.

Industry Analysis

The global respiratory infectious disease diagnostics market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, technological advancements etc.

Global Respiratory Infectious Disease Diagnostics Market - Segment Analysis

Coronavirus infections segment is expected to hold the largest market share in global blood pressure monitoring devices market

The coronavirus infections segment held the largest market share. According to the WHO, SARS-CoV-2 has spread to over 150 countries with over 460,000 confirmed cases and over 20,000 deaths as of 27th March 2020. According to an article published in the World Economic Forum in March 2020, among the 500 people being hospitalized in the U.S., 20% were aged between 20 to 44 years and 18 % were aged between 45-54 years. This factor would drive the growth of the market in the forecast period.

People with existing illnesses such as cardiovascular disease, chronic respiratory disease, hypertension, and diabetes are expected to experience a higher than average fatality rate. Moreover, according to the Chinese CDC, males are more vulnerable to becoming severely ill with the virus than women. The male fatality rate is 2.8% and the female fatality rate is 1.7%. This factor will drive the growth of market in the forecast period.

Geographical Presentation

North America dominated the global respiratory infectious disease diagnostics market and is expected to grow at the highest CAGR during the forecast period due to growing burden of respiratory diseases and higher prevalence of smoking.

According to the Centre for Disease Control and Prevention, in 2018, the prevalence of Asthma was found to be around 6.2% in male and 9.1% in female in the United States. Furthermore, around 6.2% of people were reported with chronic obstructive pulmonary diseases in the United States. Hence, these factors are expected to drive the growth of market in the forecast period.

Adoption of rapid diagnostics tests for faster diagnosis of respiratory infectious diseases is another key factor that is anticipated to augment the respiratory infectious disease diagnostics market in the region. As per CDC statistics, in May 2020, the Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel is efficient in detecting the SARS-CoV-2 virus in respiratory specimens. The USFDA also offered its Emergency Use Authorization (EUA) for this test in February 2020. These factors are expected to drive the growth of market in the forecast period.

Competitive Landscape

The global respiratory infectious disease diagnostics market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Abbott Laboratories, Thermo Fisher Scientific Inc., Alere, Inc., Koninklijke Philips N.V., Cardinal Health, COSMED, Smiths Group plc, NIHON KOHDEN CORPORATION, Becton, Dickinson and Company, and F. Hoffmann-La Roche AG. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market. For instance, in August 2020, Novacyt an international specialist in clinical diagnostics, announces the launch of its CE-Mark approved polymerase chain reaction (PCR) respiratory test panel, Winterplex. The test panel is designed to be used on any open PCR platform, including the Company's rapid, portable q32 instrument.

The global respiratory infectious disease diagnostics market report will provide access to approximately 45+ market data table,, 40+ figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Test Type
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Burden of Respiratory Diseases
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Framework
  • 4.2. Impact Analysis
  • 4.3. Opportunity

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Reimbursement Analysis

6. By Disease Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.3. Market Attractiveness Index, By Disease Type
    • 6.3.1. Coronavirus Infections *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 6.3.2. Middle East Respiratory Syndrome (MERS)
    • 6.3.3. Asthma
    • 6.3.4. Chronic Obstructive Pulmonary Disorder
    • 6.3.5. Tuberculosis
    • 6.3.6. Lung Cancer
    • 6.3.7. Others

7. By Test Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 7.3. Market Attractiveness Index, By Test Type
    • 7.3.1. Imaging Tests
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3.2. Mechanical Tests
      • 7.3.2.1. Spirometry
      • 7.3.2.2. Peak Flow Test
      • 7.3.2.3. Blood Gas Test
      • 7.3.2.4. Pulmonary Function Test
      • 7.3.2.5. Obstructive Sleep Apnea Diagnostic Test
    • 7.3.3. In-vitro Diagnostic Tests
      • 7.3.3.1. Point-of-care Test
      • 7.3.3.2. Molecular Diagnostic Test
    • 7.3.4. Other Tests

8. By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 8.3. Market Attractiveness Index, By Application
    • 8.3.1. Hospitals
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Abbott Laboratories *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Developments
    • 11.1.4. Financial Overview
  • 11.2. Becton Dickinson & Company
  • 11.3. Thermo Fisher Scientific Inc
  • 11.4. Alere, Inc
  • 11.5. Koninklijke Philips N.V
  • 11.6. Cardinal Health
  • 11.7. COSMED
  • 11.8. Smiths Group plc
  • 11.9. NIHON KOHDEN CORPORATION
  • 11.10. F. Hoffmann-La Roche AG.

12. Global Respiratory Infectious Disease Diagnostics Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us